< 1 minute read
Sep. 17, 2021

ORN0829: A Dual Orexin 1/2 Receptor Antagonist


short T1/2 dual orexin 1/2 receptor antagonist in clinical dev. for insomnia (Ph. II) from ligand-based drug design Bioorg. Med. Chem., Apr. 11, 2020 Taisho Pharmaceutical Co., Saitama, JP

Drug Hunter Team

ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking up). Chemically it has an interesting chiral 1,3-oxazinane amide motif, which is resolved in their med. chem. route through an enzymatic resolution.



Other molecules you may be interested in